What Happened?
Redwood City , CA-based Gynesonics Appointed Chris Owens as Chief Executive Officer
About the Company
At Gynesonics our mission is to design and develop new and advanced technologies for improving women`s health. We are focused on providing an incision-free option to women and the physicians who care for them, in treating symptomatic uterine fibroids. We are initiating a pivotal IDE trial in the United States to verify the safety and efficacy of the Sonata system, in preserving the uterus while treating those fibroids associated with abnormal uterine bleeding that are difficult to treat with existing technology and surgical techniques. We are committed to providing women with a safe and effective incision-free alternative to the invasive surgical techniques of hysterectomy or myomectomy for their severe menstrual symptoms associated with fibroids.
About the Person
Chris has over 20 years of medical device experience holding senior-level executive positions in both commercial and technical areas. Prior to joining Gynesonics, he was the President & CEO of IDEV Technologies from 2008-2013. IDEV was a privately held medical device company focused on the peripheral vascular market, which was acquired by Abbott in 2013. From 2005-2008, he served as Vice President of Worldwide Marketing for MicroVention, a startup medical device company in the neurovascular space that was purchased by Terumo Corporation. From 2003-2005, he was the Vice President of Global Research and Development for the Surgical Division of Bausch & Lomb.
Info Source
Press Release
Short Profile